The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2019 | CAR-T for lymphoma: new targets, real world data & resistance
Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC is joined by David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, and Barbara Savoldo, MD, PhD, of UNC School of Medicine, Chapel Hill, NC, for a roundtable discussion at the 17th International Workshop on Non-Hodgkin Lymphoma, held in Boston, MA. CAR T-cell therapies for lymphoma are discussed, including the targeting of CD5, CD17, CD19, CD20 and CD30, resistance, and real world data.
